Creating engineered B cells to produce antibodies against HIV
Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells
This study is exploring a new way to help the immune system fight HIV by modifying special cells from mice to produce powerful antibodies, and if it works well, it could lead to better ways to prevent or treat HIV in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10864988 on NIH RePORTER |
What this research studies
This research focuses on developing a method to generate broadly neutralizing antibodies (bnAbs) against HIV by engineering B cells. The approach involves taking B cells from mice, modifying them to express specific bnAb genes, and then returning these engineered cells to the host for vaccination. The goal is to understand how to optimize these engineered B cells to produce effective immune responses against HIV, with plans to test this method in non-human primates. If successful, this could lead to new strategies for preventing or treating HIV infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of HIV infection or those living with HIV who may benefit from new therapeutic approaches.
Not a fit: Patients who are not at risk for HIV or those who do not have a history of HIV infection may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative vaccines or therapies that effectively prevent or treat HIV infections.
How similar studies have performed: Other research has shown promise in using engineered B cells for antibody production, but this specific approach is novel and untested in humans.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Voss, James Even — Scripps Research Institute, the
- Study coordinator: Voss, James Even
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.